Last reviewed · How we verify
NCT06804096
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
Phase 4 trial testing Faropenem in Pneumonia, Community-Acquired in 160 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | Dr. Md. Alimur Reza |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 20 February 2025 |
| Primary completion | 30 September 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 2 locations across Bangladesh |
Drugs / interventions tested
- Faropenem (FAROPENEM) — full drug profile →
- Co-amoxiclav — full drug profile →
- Clarithromycin 500 mg — full drug profile →
Conditions studied
- Pneumonia, Community-Acquired — all drugs for Pneumonia, Community-Acquired →
- Bacterial Pneumonia — all drugs for Bacterial Pneumonia →
Sponsor
Dr. Md. Alimur Reza
Who can join
Adults 18 to 65, any sex, with Pneumonia, Community-Acquired or Bacterial Pneumonia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP). Eligible participants will be randomly assigned to one of two treatment arms. The first arm will receive faropenem at a dosage of 200 mg administered three times daily for a duration of seven days. The second arm will receive co-amoxiclav 625 mg, also three times daily, along with clarithromycin 500 mg, administered twice daily for seven days. All participants included in the study will undergo follow-up assessments over a period of four weeks. This research aims to provide valuable insights regarding the potential role of faropenem, thereby enhancing clinical outcomes and informing antibiotic stewardship in a region significantly burdened by CABP and characterized by limited treatment alternatives.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06804096
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Faropenem
Trials testing the same drug.
- NCT02381470 — Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients Wi · Phase 2 · completed
Other recruiting trials for Pneumonia, Community-Acquired
Currently open trials in the same condition.
- NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
Other Dr. Md. Alimur Reza trials
Trials by the same sponsor.
- NCT04596839 — Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19) · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06804096 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Md. Alimur Reza
- Last refreshed: 11 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06804096.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing